All Stories

  1. Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST
  2. Dietary Strategies to Modulate Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  3. Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab.
  4. 32nd European Congress on Obesity (ECO 2025)
  5. Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicentr...
  6. Balancing act: LDL-cholesterol control through plant-based vegan and Mediterranean diets
  7. What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?
  8. Generative Artificial Intelligence in Nutrition: A Revolution in Accessibility and Personalization
  9. Suppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation
  10. Small bites, big impact: The importance of evening snacks in patients with advanced chronic liver disease
  11. Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis
  12. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
  13. Malnutrition independently predicts mortality at 18 months in patients hospitalised for severe acute respiratory syndrome corona virus 2 (SARS-coV-2)
  14. New insights on portal hypertension’s screening in people with cystic fibrosis
  15. Porto-sinusoidal vascular disorder in surgical candidates for liver metastases: Prevalence, noninvasive diagnosis, and burden on surgical outcomes
  16. RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives
  17. Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis
  18. Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder
  19. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
  20. Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility
  21. Metformin and the Liver: Unlocking the Full Therapeutic Potential
  22. Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease
  23. Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
  24. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
  25. The non‐invasive evaluation of liver involvement in patients with cystic fibrosis: A prospective study
  26. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis
  27. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease
  28. Unlocking the Power of Late-Evening Snacks: Practical Ready-to-Prescribe Chart Menu for Patients with Cirrhosis
  29. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
  30. From Listing to Recovery: A Review of Nutritional Status Assessment and Management in Liver Transplant Patients
  31. Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study
  32. A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma
  33. Individual and population screening of varices needing treatment by a simple, safe and accurate test
  34. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis
  35. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
  36. Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients
  37. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease
  38. Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives
  39. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
  40. Letter to the Editor Regarding the Article “Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement” by Zhou and Collaborators
  41. Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies
  42. Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation
  43. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
  44. Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease
  45. Comparison of screening strategies with two new tests to score and diagnose varices needing treatment
  46. A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
  47. Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm
  48. Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy
  49. Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH)
  50. Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival
  51. Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis
  52. Determinants of weight, psychological status, food contemplation and lifestyle changes in patients with obesity during the COVID-19 lockdown: a nationwide survey using multiple correspondence analysis
  53. Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm
  54. Real-life prevalence of Metabolic Associated Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a tertiary obesity clinic in Italy
  55. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients
  56. Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients
  57. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
  58. Intestinal failure associated liver disease after weaning off home parenteral nutrition: a 12-month follow up
  59. Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years
  60. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment
  61. Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice
  62. Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges
  63. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
  64. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
  65. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
  66. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
  67. The role of liver and spleen elastography in advanced chronic liver disease
  68. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
  69. Pattern of macrovascular invasion in hepatocellular carcinoma
  70. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease
  71. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
  72. Liver Measurement Stiffness Can Predict Chemotherapy-related Liver Injury and Complications after Surgery for Liver Metastases
  73. Liver and Spleen Stiffness in Vascular Liver Disease
  74. The changing scenario of hepatocellular carcinoma in Italy: an update
  75. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
  76. Malnutrition in hospitalized patients with SARS-CoV-2 infection
  77. Transition of patients with chronic intestinal failure from paediatric to adult center
  78. Clinical impact of sarcopenia assessment in patients with liver cirrhosis
  79. Monofocal hepatocellular carcinoma: How much does size matter?
  80. Reply to: “Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma”
  81. Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?
  82. UEG Week 2020 Poster Presentations
  83. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma
  84. Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
  85. Reply to: “Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma”
  86. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes
  87. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study
  88. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments
  89. Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk
  90. Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients
  91. Non-invasive tests for the prediction of primary hepatocellular carcinoma
  92. Non-invasive tests for the prediction of post-hepatectomy liver failure in the elderly
  93. Predictive factors for hepatocellular carcinoma recurrence after curative treatments
  94. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients
  95. Pancreatic ultrasound elastography is not useful to predict the risk of pancreatic fistulas after pancreatic resection
  96. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation
  97. Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study
  98. Spleen stiffness measurement predicts the development of primary hepatocellular carcinoma better than hepatic venous pressure gradient
  99. Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C
  100. A novel spleen‐dedicated stiffness measurement by FibroScan® improves the screening of high‐risk oesophageal varices
  101. Sound Conclusions: How Splenic Elastography May Decrease the Need for Endoscopic Variceal Surveillance
  102. IDDF2019-ABS-0108 Hepatic decompensation risk is reduced, but not eliminated after direct-acting antivirals: the role of spleen stiffness measurement
  103. Longitudinal evaluation of liver stiffness in three pediatric patients with veno‐occlusive disease
  104. Editorial: collagen proportionate area as a prognostic indicator in NAFLD
  105. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study
  106. Reply to correspondence concerning: “Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection”
  107. Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review
  108. “Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?”
  109. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection
  110. Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients
  111. Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome
  112. Prediction of posthepatectomy liver failure: Role of SSM and LSPS
  113. Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study
  114. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients
  115. How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests
  116. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals
  117. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease
  118. Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update
  119. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals
  120. Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808]
  121. Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals
  122. Pancreatic ultrasound elastography and its clinical use in predicting the risk of pancreatic fistulas after pancreatic resection
  123. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study
  124. A spleen stiffness measurement-based model for recognition of high risk varices: Baveno VI criteria and beyond
  125. Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients
  126. Correction to: Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness
  127. PC.01.2 A SPLEEN STIFFNESS MEASUREMENT-BASED MODEL FOR THE RECOGNITION OF HIGH RISK VARICES: BAVENO VI CRITERIA AND BEYOND
  128. P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C
  129. A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond
  130. IL28 polymorphism and HCC after DAAs for chronic hepatitis C
  131. Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease
  132. Spleen Stiffness by Ultrasound Elastography
  133. Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness
  134. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study
  135. DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods
  136. Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients
  137. Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens
  138. The role of Spleen Stiffness measurement as predictor of HCC recurrence after curative resection in cirrhotic patients
  139. DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods
  140. The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients
  141. Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens
  142. Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients
  143. Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT
  144. Gut Microbiota and Celiac Disease